| Symbol | SNGX |
|---|---|
| Name | SOLIGENIX, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 29 EMMONS DRIVE,SUITE B-10, PRINCETON, New Jersey, 08540, United States |
| Telephone | +1 609 538-8200 |
| Fax | — |
| — | |
| Website | https://www.soligenix.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000812796 |
| Description | Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19). Additional info from NASDAQ: |
New Form 424B3 - SOLIGENIX, INC. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001104659-26-092711 <b>Size:</b> 1 MB
Read moreNew Form 424B3 - SOLIGENIX, INC. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001104659-26-092707 <b>Size:</b> 1 MB
Read moreNew Form 424B3 - SOLIGENIX, INC. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001104659-26-092701 <b>Size:</b> 1 MB
Read moreNew Form 424B3 - SOLIGENIX, INC. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0001104659-26-092698 <b>Size:</b> 1 MB
Read moreSoligenix Announces Recent Updates and Second Quarter 2026 Financial Results
Read moreSoligenix Announces Recent Updates and Second Quarter 2026 Financial Results
Read moreNew Form ARS - SOLIGENIX, INC. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001104659-26-089799 <b>Size:</b> 1 MB
Read moreNew Form PRER14A - SOLIGENIX, INC. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001104659-26-086341 <b>Size:</b> 6 MB
Read moreNew Form SCHEDULE 13G - SOLIGENIX, INC. <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0002103370-26-000002 <b>Size:</b> 44 KB
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read more